Physician profile
Dean B Kubacz
NPI 1023276896
$2,044.55
in general payments reported to CMS, 2019-2025
28 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $224 · 2021: $432 · 2022: $443 · 2023: $430 · 2024: $369 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $470.70 | 2020-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $252.04 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $158.30 | 2020-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $142.73 | 2021-2024 | |
| Lilly USA, LLC | $110.35 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $105.13 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.23 | 2021-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $86.58 | 2023-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $63.98 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $54.75 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $53.54 | 2022-2024 | |
| Medtronic, INC. | $51.03 | 2023 | Intellis Adaptivestim |
| Takeda Pharmaceuticals U.S.A., INC. | $50.16 | 2021 | |
| Genentech USA, INC. | $49.20 | 2020-2021 | |
| Exact Sciences Corporation | $37.91 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $36.31 | 2021-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Pfizer INC. | $30.72 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.03 | 2021-2025 | Jardiance |
| Lundbeck LLC | $25.12 | 2022 | |
| Mckesson Medical-Surgical, INC. | $21.74 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $20.70 | 2023 | |
| Alnylam Pharmaceuticals INC. | $19.00 | 2024 | Onpattro |
| Daiichi Sankyo INC. | $16.56 | 2021 | |
| Merck Sharp & Dohme LLC | $15.48 | 2020 | |
| Inspire Medical Systems, INC. | $14.36 | 2023 | Inspire |
| Redhill Biopharma INC. | $12.82 | 2020 | |
| Evofem Biosciences, INC. | $12.76 | 2021 | |
| Organon LLC | $9.32 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Kubacz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.